Biocon Limited

BIOCON

INE376G01013

Biotechnology & Medical Research

Market Closed - NSE India S.E. Other stock markets 05:10:29 16/07/2024 pm IST			5-day change	1st Jan Change
353.4 ^INR	-1.60%		-3.61%	+41.56%

28/06	India plans incentives for diabetes, obesity drug makers in 2026, government official says	RE
24/06	EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites	CI

Biocon Limited Provides Tax Rate Guidance for the Fiscal Years of 2012 and 2013

January 25, 2012 at 03:00 pm IST

Biocon Limited provided tax rate guidance for the fiscal years of 2012 and 2013. For the years 2012 and 2013 the company expects their overall tax rate about 18% to 20%, respectively.

Latest news about Biocon Limited

India plans incentives for diabetes, obesity drug makers in 2026, government official says	28/06	RE
EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites	24/06	CI
Biocon Arm Gets European Regulator's Nod to Manufacture Bevacizumab at Indian Facility	24/06	MT
Biocon Gets Four Observations from US FDA for Visakhapatnam, India Facility	24/06	MT
India's Biocon seeks partner to test generic Wegovy, Ozempic in China	20/06	RE
Biocon Gets Three Observations from US FDA after Visakhapatnam, India Unit Inspection	17/06	MT
Indian Equities End Flat on Tuesday; ONGC Shares Rise 6%	11/06	MT
Biocon Names Interim CFO	11/06	MT
Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer	11/06	CI
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06	RE
Biocon Limited Receives Approval from the U.S. Food and Drug Administration	03/06	CI
Biocon Limited Receives Show Cause Notice from the Assistant Commissioner of Customs, Chennai	31/05	CI
INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh	24/05	RE
Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	24/05	MT
Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc	24/05	CI
US FDA Approves Samsung Bioepis' Eye Disease Drug Opuviz	23/05	MT
Jefferies Adjusts Biocon’s Price Target to INR230 From INR250, Keeps at Underperform	17/05	MT
Biocon's Consolidated Net Profit Declines in Fiscal Q4	17/05	MT
India's Biocon posts Q4 profit fall as higher raw material costs bite	16/05	RE
Transcript : Biocon Limited, Q4 2024 Earnings Call, May 16, 2024	16/05
Biocon Limited Proposes Final Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024	16/05	CI
Biocon Limited Reports Earnings Results for the Full Year Ended March 31, 2024	16/05	CI
Biocon Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	16/05	CI
Biocon Signs Deal with Medix for Commercialization of Chronic Weight Management Drug in Mexico	13/05	MT
Biocon Limited Signs Semi-Exclusive Distribution and Supply Deal for the Commercialization of Generic Saxenda® (Liraglutide) in Mexico with Medix	13/05	CI

Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.

Sector

Biotechnology & Medical Research

Calendar

25/07/2024 - Q1 2025 Earnings Release (Projected)

Related indices

NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Biocon Limited

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

353.4 INR

Average target price

310 INR

Spread / Average Target

-12.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOCON LIMITED	+41.56%	513.14Cr
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	13TCr
REGENERON PHARMACEUTICALS, INC.	+24.67%	12TCr
ARGENX SE	+25.44%	2.77TCr
BIONTECH SE	-17.74%	2.03TCr
GENMAB A/S	-15.17%	1.68TCr
BEIGENE, LTD.	-15.21%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+11.91%	1.48TCr
WUXI APPTEC CO., LTD.	-47.10%	1.46TCr
SAREPTA THERAPEUTICS, INC.	+54.50%	1.44TCr

Bio Therapeutic Drugs

Biocon Limited

Equities

BIOCON

INE376G01013

Biotechnology & Medical Research

Biocon Limited Provides Tax Rate Guidance for the Fiscal Years of 2012 and 2013

Latest news about Biocon Limited

Chart Biocon Limited

Company Profile

Income Statement Evolution

Ratings for Biocon Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs